Provectus Biopharmaceuticals, Inc.

PVCT • Biotechnology

$0.06

▲ +0.00 (+3.90%)

Current price

EarningsLatest report: Jun 30, 2026

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$25.22M

Growth

-11.2%

Cash Flow

0/5

Trend

Negative

Evidence

Weak liquidity · 0.08Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:33 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.06

Change3.90%

Shares Out420.28M

Market Cap$25.22M

Enterprise Value$28.80M

52W Range0.04 - 0.09

Beta0.87

P/E-5.31

P/B-4.01

P/FCF-10.40

EV/EBITDA-8.74

EV/FCF-11.88

Price$0.06

Change3.90%

Shares Out420.28M

Market Cap$25.22M

Enterprise Value$28.80M

52W Range0.04 - 0.09

Beta0.87

P/E-5.31

P/B-4.01

P/FCF-10.40

EV/EBITDA-8.74

EV/FCF-11.88

Earnings Yield-18.83%

FCF Yield-9.62%

Dividend Yield0.00%

Gross Margin99.45%

Oper. Margin-14.41%

Profit Margin-16.16%

Debt/Eq-0.47

Current Ratio0.08

Quick Ratio0.08

Revenue 5Y-11.15%

Volume199.91K

Avg Volume178.64K

EPS Surprise-0.01

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

20/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

20/100

Why this score▼

Weak liquidity · 0.08Negative growth trendWeak profitability

Analyst view

No analyst data available now.

Company Overview

IPO: 1/15/1997

Industry: Biotechnology

P/B i: -4.01

Debt / Equity i: -0.47

Operating Margin: -1441.28%

Net Margin: -1615.81%

ROE i: -

ROIC: -

Financial Health

Score4 / 20

Debt / Equity: -0.47

Current Ratio: 0.08

Quick Ratio: 0.08

Status: HighRisk

Warnings

Weak Liquidity
Weak quick ratio

Insider Transactions

Recent executive and insider activity

Pershing Edward

Transaction: 06/30/2026

BUY

Change

+45,860

Price

Not reported

Filing

07/02/2026

Type

BUY

Bailey Webster

Transaction: 06/30/2026

BUY

Change

+48,917

Price

Not reported

Filing

06/30/2026

Type

BUY

Lacey John III

Transaction: 06/30/2026

BUY

Change

+48,917

Price

Not reported

Filing

06/30/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Pershing Edward	BUY	+45,860	Not reported	06/30/2026	07/02/2026
Bailey Webster	BUY	+48,917	Not reported	06/30/2026	06/30/2026
Lacey John III	BUY	+48,917	Not reported	06/30/2026	06/30/2026
Rodrigues Dominic	BUY	+45,860	Not reported	06/30/2026	06/30/2026
Pershing Edward	SELL	0	$2.86	06/05/2026	06/05/2026
Pershing Edward	BUY	+9,436	Not reported	06/05/2026	06/05/2026
Pershing Edward	BUY	0	$2.86	05/28/2026	05/29/2026
Pershing Edward	SELL	0	$2.86	05/23/2026	05/26/2026
Pershing Edward	BUY	+32,089	Not reported	05/23/2026	05/26/2026
Pershing Edward	SELL	0	$2.86	05/15/2026	05/15/2026
Pershing Edward	BUY	+22,651	Not reported	05/15/2026	05/15/2026
Pershing Edward	SELL	0	$2.86	05/07/2026	05/07/2026
Pershing Edward	BUY	+18,876	Not reported	05/07/2026	05/07/2026
Pershing Edward	SELL	0	$2.86	04/29/2026	04/29/2026
Pershing Edward	BUY	+30,202	Not reported	04/29/2026	04/29/2026
Pershing Edward	SELL	0	$2.86	04/04/2026	04/06/2026
Pershing Edward	BUY	+33,977	Not reported	04/04/2026	04/06/2026
Pershing Edward	BUY	0	$2.86	03/25/2026	03/26/2026
Pershing Edward	SELL	0	$2.86	03/20/2026	03/20/2026
Pershing Edward	BUY	+49,067	Not reported	03/20/2026	03/20/2026

About the Company

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy. This treatment is being explored for a range of adult solid tumor malignancies, encompassing melanoma and various gastrointestinal cancers (such as hepatocellular carcinoma, metastatic colorectal cancer to the liver, metastatic neuroendocrine tumors to the liver, and metastatic uveal melanoma to the liver). It also targets pediatric solid tumors, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Additionally, Provectus is advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) to combat a broad spectrum of conditions. These include adult solid tumors (such as head and neck, breast, testicular, and colorectal cancers), pediatric blood cancers like leukemia, acute respiratory syndromes such as coronavirus, infections caused by multi-drug resistant bacteria (specifically Gram-negative bacteria), and certain ocular conditions, notably infectious keratitis. Furthermore, the company is progressing PH-10, an investigational immuno-dermatology agent designed to address inflammatory skin conditions like psoriasis and atopic dermatitis. Originally established in 2002, the company was initially named Provectus Pharmaceuticals, Inc., before rebranding as Provectus Biopharmaceuticals, Inc. in December 2013. Its operations are headquartered in Knoxville, Tennessee.

Source - link

Peers

BBIXF CLYYF CYYNF DTCFF MBXBF MMIRF NXSCF SEOVF SPHRF WOWU

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase

KNOXVILLE, Tenn., July 22, 2026 (GLOBE NEWSWIRE) -- VisiRose, Inc. (“VisiRose” or the “Company”), the clinical-stage ophthalmology subsidiary of Provectus Biopharmaceuticals, Inc. (“Provectus”) (OTCQB: PVCT), a clinical-stage biotechnology company developing pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient (“API”) as a platform therapeutic, today announced it has been selected to present at the Emerging Company Showcase at ESCRS iNovation ® Day 2026, to be held September 11th at Excel London in the United Kingdom.

GlobeNewsWire

Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose

Peer-reviewed preclinical melanoma research finds Provectus's synthetic small molecule can both stimulate anti-tumor immunity and suppress peripheral immune cells at the same dose. A recently published peer-reviewed medical journal article in Molecular Therapy: Oncology by OncoThAI researchers at the University of Lille in France shows that RBS can be immunostimulatory in tumor cells and immunosuppressive in peripheral immune cells at the same dose.

GlobeNewsWire

Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections

KNOXVILLE, Tenn., June 30, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT), a clinical-stage biotechnology company developing pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient (“API”) as a platform therapeutic, and VisiRose, Inc. (“VisiRose”), Provectus's clinical-stage ophthalmology subsidiary, today announced the issuance of U.S. Patent No. 12,661,335, titled “Halogenated Xanthene-Containing Topical Anti-Gram-Positive Bacterial Ophthalmic Composition and Method.” The patent covers a topical eye drop formulation of RBS API for treating Gram-positive bacterial keratitis, including drug-resistant strains such as MRSA and vancomycin-resistant Enterococcus.

GlobeNewsWire

Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections

New IP covers topical rose bengal sodium ophthalmic composition against MRSA and other resistant Gram-positive bacteria without requiring light activation. VisiRose to hold exclusive ophthalmic license. KNOXVILLE, Tenn., June 30, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company") (OTCQB: PVCT), a clinical-stage biotechnology company developing pharmaceutical grade rose bengal sodium ("RBS") active pharmaceutical ingredient ("API") as a platform therapeutic, and VisiRose, Inc.

Globe News Wire

Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)

Under Veripure, Provectus is supplying qualified medical researchers with the same pharmaceutical grade rose bengal sodium API used in clinical trials. Veripure is also a quality benchmark, distinguishing program-associated medical research on PV-10 from research conducted using commercially sourced rose bengal of variable purity and uncharacterized content.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2013-03-14	-0.015	-0.02	-0.005
2012-11-08	-0.015	-0.02	-0.005
2012-08-08	-0.02625	-0.03	-0.00375
2012-05-09	-0.03333	-0.04	-0.00667
2012-03-14	-0.07	-0.05	0.02
2011-08-09	-0.06	-0.04	0.02
2011-05-10	-0.03333	-0.05	-0.01667
2011-03-16	-0.01286	-0.02	-0.00714
2010-11-15	-0.045	-0.09	-0.045
2010-08-13	-0.05	-0.1	-0.05
2010-05-17	-0.05	-0.16	-0.11
2010-03-31	-0.04	-0.05	-0.01